A link between depression and bone metabolism: what are the implications for treatment?

References

• Eaton WW. Medical and Psychiatric Comorbidity Over the Lifecourse. American Psychiatric Publishing Inc., VA, USA (2005).
   Google Scholar
• Cizza G, Ravn P, Chrousos G. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab.12, 198–203 (2001).
   PubMed Web of Science ®Google Scholar
• Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos. Int.19, 1–12 (2008).
   PubMed Web of Science ®Google Scholar
• Eaton WW, Shao H, Nestadt G et al. Population-based study of first onset and chronicity in major depressive disorder. Arch. Gen. Psychiatry65, 513–520 (2008).
   PubMed Web of Science ®Google Scholar
• WHO. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis: report of the WHO Study Group. Word Health Organ. Tech. Rep. Ser.843, 1–126 (1994).
   PubMed Web of Science ®Google Scholar
• Raisz L. Physiology and pathophysiology of bone remodeling. Clin. Chem.48, 1353–1358 (1999).
   Google Scholar
• Williams LJ, Pasco JA, Jacka FN et al. Depression and bone metabolism. Psychother. Psychosom.78, 16–25 (2009).
   PubMedGoogle Scholar
• Licinio J, Wong M. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-response systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry44, 317–327 (1999).
   Google Scholar
• Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos G. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med.128(2), 127–137 (1998).
   PubMed Web of Science ®Google Scholar
• De Berardis D, Campanella D, Gambi F et al. The role of C-reactive protein in mood disorders. Int. J. Immunopathol. Pharmacol.19(4), 721–725 (2006).
   PubMedGoogle Scholar
• Taylor MJ, Goodwin GM. Long-term prophylaxis in bipolar disorder. CNS Drugs20, 303–310 (2006).
   PubMed Web of Science ®Google Scholar
• Romas E, Martin T. Cytokines in the pathogenesis of osteoporosis. Osteoporos. Int.7, S47–S53 (1997).
   Web of Science ®Google Scholar
• Carroll BJ, Curtis GC, Davies BM et al. Urinary free cortisol excretion in depression. Psychol. Med.6(1), 43–50 (1976).
   PubMed Web of Science ®Google Scholar
• Watson S, Gallegher P, Ritchie J et al. Hypothalamic–pituitary–adrenal axis function in patients with bipolar disorder. Br. J. Psych.184, 496–502 (2004).
   PubMed Web of Science ®Google Scholar
• Kann P, Laudes M, Piepkorn B et al. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin. Rheumatol.20(1), 25–29 (2001).
   PubMedGoogle Scholar
• Reynolds RM, Dennison EM, Walker BR et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif. Tissue Int.77, 134–138 (2005).
   PubMed Web of Science ®Google Scholar
• Dennison E, Hindmarsh P, Fall C et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J. Clin. Endocrinol. Metab.84, 3058–3063 (1999).
   PubMedGoogle Scholar
• Lake CR, Pickar D, Ziegler MG et al. High plasma norepinephrine levels in patients with major affective disorder. Am. J. Psychiatry139(10), 1315–1318 (1982).
   PubMed Web of Science ®Google Scholar
• Maes M, Vandewoude M, Schotte C et al. Positive relationship between the catecholaminergic turnover and the DST results in depression. Psychol. Med.20(3), 493–499 (1990).
   PubMedGoogle Scholar
• Rehman H, Masson E. Neuroendocrinology of female aging. Gend. Med.2, 41–56 (2005).
   PubMedGoogle Scholar
• Carnahan R, Perry P. Depression in aging men: the role of testosterone. Drugs Aging21, 361–376 (2004).
   PubMed Web of Science ®Google Scholar
• Shoback D, Marcus R, Bikle D. Metabolic bone disease. In: Basic and Clinical Endocrinology. Greenspan F, Gardner D (Eds). Lange Medical Books/McGraw-Hill, NY, USA 295–361 (2004).
   Google Scholar
• Khosla S, Melton LJ 3rd, Atkinson EJ et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab.83(7), 2266–2274 (1998).
   PubMed Web of Science ®Google Scholar
• Herrán A, Amado JA, García-Unzueta MT et al. Increased bone remodeling in first-episode major depressive disorder. Psychosom. Med.62, 779–782 (2000).
   PubMedGoogle Scholar
• Kahl KG, Greggersen W, Rudolf S et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom. Med.68, 669–674 (2006).
   PubMedGoogle Scholar
• Altindag O, Altindag A, Asoglu M et al. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract.61, 416–420 (2007).
   PubMedGoogle Scholar
• Michelson D, Stratakis C, Hill L et al. Bone mineral density in women with depression. N. Engl. J. Med.335, 1176–1181 (1996).
   PubMed Web of Science ®Google Scholar
• Yazici K, Akinci A, Sütçü A, Ozçakar L. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res.117, 271–275 (2003).
   PubMedGoogle Scholar
• Eskandari F, Martinez PE, Torvik S et al. Low bone mass in premenopausal women with depression. Arch. Intern. Med.167, 2329–2336 (2007).
   PubMedGoogle Scholar
• Petronijevic M, Petronijevic N, Ivkovic M et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone42, 582–590 (2008).
   PubMedGoogle Scholar
• Kavuncu V, Kuloglu M, Kaya A et al. Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med. J.43, 101–108 (2002).
   PubMedGoogle Scholar
• Alexopoulos GS, Katz IR, Reynolds CF et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad. Med.1–86 (2001).
   PubMed Web of Science ®Google Scholar
• Battaglino R, Vokes M, Schulze-Späte U et al. Fluoxetine treatment increases trabecular bone formation in mice. J. Cell. Biochem.100, 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Warden SJ, Haney EM. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J. Musculoskelet. Neuronal Interact.8, 121–132 (2008).
   PubMedGoogle Scholar
• Bonnet N, Bernard P, Beaupied H et al. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol. Appl. Pharmacol.221(1), 111–118 (2007).
   PubMedGoogle Scholar
• Battaglino R, Fu J, Späte U et al. Serotonin regulates osteoclast differentiation through its transporter. J. Bone Miner. Res.19(9), 1420–1431 (2004).
   PubMed Web of Science ®Google Scholar
• Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause15(6), 1176–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Mezuk B, Eaton WW, Golden SH et al. Depression, antidepressants and bone mineral density in a population-based cohort. J. Gerontol. A. Biol. Sci. Med. Sci.63, 1410–1415 (2008).
   PubMedGoogle Scholar
• Diem SJ, Blackwell TL, Stone KL et al. The study of osteoporotic fractures. Use of antidepressants and rates of hip bone loss in older women: Arch. Intern. Med.167, 1240–1245 (2007).
   PubMed Web of Science ®Google Scholar
• Bonnet N, Beaupied H, Vico L et al. Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J. Bone Min. Res.22(4), 578–588 (2007).
   PubMedGoogle Scholar
• Veehof L, Stewart R, Haaijer-Ruskamp F et al. The development of polypharmacy. A longitudinal study. Fam. Pract.17(3), 261–267 (2000).
   PubMed Web of Science ®Google Scholar
• Laroche ML, Charmes JP, Nouaille Y et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br. J. Clin. Pharmacol.63, 177–186 (2007).
   PubMed Web of Science ®Google Scholar
• Mort JR, Aparasu RR. Prescribing potentially inappropriate psychotropic medications to the ambulatory elderly. Arch. Intern. Med.160(18), 2825–2831 (2000).
   PubMed Web of Science ®Google Scholar
• Lindström K, Ekedahl A, Carlsten A et al. Can selective serotonin inhibitor drugs in elderly patients in nursing homes be reduced? Scand. J. Prim. Health Care25(1), 3–8 (2007).
   PubMed Web of Science ®Google Scholar
• Takkouche B, Montes-Martinez A, Gill S, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf.30, 171–184 (2007).
   PubMed Web of Science ®Google Scholar
• Vestergaard P. Fracture risks of antidepressants. Expert Rev. Neurother.9(1), 137–141 (2009).
   PubMed Web of Science ®Google Scholar
• Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and Type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care31, 2383–2390 (2008).
   PubMed Web of Science ®Google Scholar
• Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am. J. Prev. Med.23, 51–61 (2002).
   PubMed Web of Science ®Google Scholar
• Markowitz S, Friedman MA, Arent SM. Understanding the relation between obesity and depression: causal mechanisms and implications for treatment. Clin. Psychol. Sci. Pract.15, 1–20 (2008).
   Web of Science ®Google Scholar
• Buist DS, LaCroix AZ, Black DM et al. Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. J. Am. Geriatr. Soc.48(9), 1126–1131 (2000).
   PubMedGoogle Scholar